darglitazone has been researched along with Arteriosclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabré, A; Camejo, G; Hultén, LM; Norén, K; Pedreño, J; Svensson, L; Vallvé, JC; Wiklund, O | 1 |
1 other study(ies) available for darglitazone and Arteriosclerosis
| Article | Year |
|---|---|
Fatty acids modulate the effect of darglitazone on macrophage CD36 expression.
Topics: Arteriosclerosis; CD36 Antigens; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Macrophages; Receptors, Immunologic; Receptors, Scavenger; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones | 2003 |